Media coverage about Galmed Pharmaceuticals (NASDAQ:GLMD) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Galmed Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.0338922684216 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Several research analysts recently issued reports on the stock. Maxim Group reiterated a “buy” rating and issued a $14.00 target price (up from $9.00) on shares of Galmed Pharmaceuticals in a research report on Monday, July 31st. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Wednesday, August 2nd. HC Wainwright upped their target price on shares of Galmed Pharmaceuticals from $12.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, ValuEngine upgraded shares of Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 17th.

Galmed Pharmaceuticals (NASDAQ:GLMD) traded down 1.9162% during mid-day trading on Wednesday, reaching $7.8467. 3,927 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $7.78 and its 200 day moving average price is $5.94. The firm’s market cap is $95.88 million. Galmed Pharmaceuticals has a one year low of $2.78 and a one year high of $8.87.

Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Monday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Galmed Pharmaceuticals had a negative net margin of 1,443.98% and a negative return on equity of 141.13%. The firm had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.29 million. On average, equities analysts forecast that Galmed Pharmaceuticals will post ($0.94) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

Insider Buying and Selling by Quarter for Galmed Pharmaceuticals (NASDAQ:GLMD)

Receive News & Stock Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.